- Report
- November 2024
- 150 Pages
United Kingdom
From €1893EUR$1,991USD£1,590GBP
- Report
- November 2024
- 130 Pages
Asia Pacific
From €1767EUR$1,859USD£1,485GBP
- Report
- November 2024
- 90 Pages
Australia
From €1767EUR$1,859USD£1,485GBP
- Report
- July 2022
- 234 Pages
Global
From €3394EUR$3,570USD£2,851GBP
- Book
- February 2025
- 432 Pages
- Book
- March 2024
- 528 Pages
The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more